Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.50
Bid: 15.00
Ask: 16.00
Change: -2.50 (-13.89%)
Spread: 1.00 (6.667%)
Open: 15.50
High: 16.50
Low: 15.25
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Angus Energy exceeds monthly production targets

Wed, 12th Oct 2022 14:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Angus Energy PLC - oil and gas development company focused on UK assets - Says that hourly throughput rates through its process plant now exceeds its October target production rate of 6 million standard cubic feet per day with well pressures holding in the high forties. Condensate production has stabilised at or around 120 barrels per day. Says side-track planning progresses with an adjustment to spud date to October 24 to 26 from October 20, 2022, in order to accommodate a potential supply chain issue.

----------

Canadian Overseas Petroleum Ltd - Calgary, Canada-based oil and gas company operating in Nigeria and US state of Wyoming - Receives gas flare approval for its operated 85% WI Barron Flats Shannon Unit, from Wyoming Oil & Gas Conservation Commission. "This is a great result as it will allow the company to manage increased gas production with associated high working pressures as the miscible bank moves in the injection patterns. In addition, our oil production from the Shannon Unit will increase as production rates have been restricted in certain wells due to these issues," says Chief Executive Arthur Millholland.

----------

Kistos PLC - London-based energy industry investor with licenses in the Netherlands - Says High Court of Justice of England & Wales approves cancellation of bonus shares issued on Monday and the credit of EUR50.0 million to the company's share premium account. Expects the court order approving the capital reduction, and a statement of capital approved by the court, to be filed with the Registrar of Companies no later than October 22.

----------

UniVision Engineering Ltd - Hong Kong-based CCTV and surveillance system company - Enters loan agreement with Webright Ventures Ltd to borrow GBP1.4 million. Says the loan will be unsecured, will have a period of three months and an interest rate of 8% per year. Around half the loan will be used as funds set aside ahead of the hearing of the winding-up petition against UniVision, which was announced back in January, and is due to be heard in court in Hong Kong on October 18. Adds that it is still working with its auditors to complete its audit and publish its annual report, after which the company's shares are expected to begin trading on London's AIM.

----------

Angle PLC - Surrey, England-based medical diagnostics company - Signs distribution agreement with Promedeus SRO to enable and support the roll out of the US Food & Drug Administration cleared and CE marked Parsortix PC1 system across the Czech Republic for its intended use in metastatic breast cancer. Says Promedeus, a part of the Vendeavour Group, a Private Equity fund with a focus on healthcare, has considerable expertise in distributing a range of advanced medical equipment into the Czech hospital and primary care markets with a track record for delivering high quality physician education and customer care. "We are pleased to enter into this agreement with Promedeus and are encouraged by the efforts that the Promedeus team has already made to understand the benefits that the Parsortix system can bring to their oncology focused customer base. They have a strong track record and local knowledge which can help support the development of a new market for Parsortix," says Founder & Chief Executive Andrew Newland.

----------

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.